The Food and Drug Administration (FDA) has a labyrinthine approval process for new drugs. This is good news for consumers, bad news for drug companies and an opportunity for short-term traders. The approval process creates intense price volatility among the publicly traded companies that are involved, particularly those early stage companies with little revenue.

There are several companies with approvals pending before the FDA that a trader can build either long or short positions around to take advantage of this volatility.

Early Stage Biotech
In February 2008, the FDA accepted a review request by Cypress Bioscience (Nasdaq:CYPB) and Forest Laboratories (NYSE:FRX) for a new drug application for Milnacipran, a drug for use in treating fibromyalgia syndrome. Milnacipran was approved for use in Austria but Cypress is attempting to bring it to North America. An approval or rejection decision is expected at the end of October 2008. If approved the drug can legally be marketed and sold. (To begin with the analysis basics, read Measuring The Medicine Makers.)

Cypress Bioscience is an early-stage biotechnology company that had only $15 million in revenue in the first six months of 2008. Almost all of the revenue was payments from Forest Labs in connection with Milnacipran. A negative decision from the FDA might be devastating to the company, although the company did have $153.4 million in cash, cash equivalents and short-term investments as a cushion at the end of the June quarter. Either way, a binary outcome is probable.

Forest Labs is a more diversified company with revenue in its latest fiscal year of $3.8 billion so the upcoming FDA decision on Milnacipran will have less impact on this company. Forest Lab's two main drugs are Lexapro, used to treat depression, which represented 66% of sales, and Namenda, used to treat Alzheimer's disease, which was 24% of sales in fiscal 2008.

Ligand Pharmaceuticals (Nasdaq:LGND) is another early-stage drug company with a new drug application pending before the FDA. Ligand technology was used in the development of Fablyn, which can treat osteoporosis, and was developed in collaboration with Pfizer (NYSE:PFE). An FDA panel gave the chances for approval a boost in early September 2008, when it said the drug might prove more beneficial to patients given the risks. Ligand had only $9.7 million in revenues the first six months of 2008. The company is not solely dependent on Fablyn, as it has collaborations with other large drug companies including Wyeth (NYSE:WYE) and GlaxoSmithKline plc (NYSE:GSK). A decision is expected sometime before the end of 2008 and if approved Ligand will receive royalty payments and cash.

Discovery Laboratories (Nasdaq:DSCO) is seeking approval for a drug called Surfaxin for the prevention of respiratory distress syndrome (RDS) in premature infants. The company only had about $4.5 million in revenue in the first six months of 2008. The FDA issued an approvable letter in May 2008, and Discovery Labs is expected to respond to that letter shortly. If the response is designated a "class 1" resubmission, then a decision is expected from the FDA before the end of the year.

Bottom Line
Volatility is the lifeblood of a trader, and the binary outcome of the FDA new drug application process provides plenty of it.

For more on trading the biotech industry and the drug approval process, read The Ups And Downs Of Biotechnology.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!